Have a feature idea you'd love to see implemented? Let us know!

SYRS Syros Pharmaceuticals Inc

Price (delayed)

$2.265

Market cap

$60.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.34

Enterprise value

$40.3M

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop ...

Highlights
SYRS's EPS is up by 14% since the previous quarter
Syros Pharmaceuticals's debt has decreased by 3.4% YoY
SYRS's net income is down by 38% YoY but it is up by 9% from the previous quarter
Syros Pharmaceuticals's quick ratio has decreased by 37% YoY but it has increased by 12% QoQ
The equity has shrunk by 142% QoQ and by 109% YoY
The gross profit has dropped by 54% year-on-year and by 41% since the previous quarter

Key stats

What are the main financial stats of SYRS
Market
Shares outstanding
26.81M
Market cap
$60.72M
Enterprise value
$40.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
21.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.72
Earnings
Revenue
$4.15M
EBIT
-$126.24M
EBITDA
-$124.61M
Free cash flow
-$109.54M
Per share
EPS
-$4.34
Free cash flow per share
-$2.79
Book value per share
-$0.24
Revenue per share
$0.11
TBVPS
$2.72
Balance sheet
Total assets
$106.72M
Total liabilities
$113.07M
Debt
$60.66M
Equity
-$6.35M
Working capital
$60.4M
Liquidity
Debt to equity
-9.55
Current ratio
3.46
Quick ratio
3.31
Net debt/EBITDA
0.16
Margins
EBITDA margin
-3,004%
Gross margin
100%
Net margin
-3,171.7%
Operating margin
-2,895.7%
Efficiency
Return on assets
-94.4%
Return on equity
-853.3%
Return on invested capital
-199%
Return on capital employed
-153.6%
Return on sales
-3,043.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SYRS stock price

How has the Syros Pharmaceuticals stock price performed over time
Intraday
-10.12%
1 week
13.25%
1 month
19.21%
1 year
-5.23%
YTD
-70.92%
QTD
5.35%

Financial performance

How have Syros Pharmaceuticals's revenue and profit performed over time
Revenue
$4.15M
Gross profit
$4.15M
Operating income
-$120.11M
Net income
-$131.56M
Gross margin
100%
Net margin
-3,171.7%
Syros Pharmaceuticals's net margin has shrunk by 198% YoY and by 53% QoQ
The operating margin has plunged by 81% YoY and by 60% from the previous quarter
The gross profit has dropped by 54% year-on-year and by 41% since the previous quarter
SYRS's revenue has shrunk by 54% YoY and by 41% QoQ

Growth

What is Syros Pharmaceuticals's growth rate over time

Valuation

What is Syros Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
21.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.72
SYRS's EPS is up by 14% since the previous quarter
The equity has shrunk by 142% QoQ and by 109% YoY
SYRS's revenue has shrunk by 54% YoY and by 41% QoQ
The price to sales (P/S) is 27% lower than the 5-year quarterly average of 29.5 and 25% lower than the last 4 quarters average of 28.4

Efficiency

How efficient is Syros Pharmaceuticals business performance
SYRS's return on invested capital has dropped by 162% year-on-year and by 3.2% since the previous quarter
SYRS's ROA has plunged by 127% YoY and by 3.2% from the previous quarter
The ROE has plunged by 109% from the previous quarter
SYRS's ROS has dropped by 53% since the previous quarter

Dividends

What is SYRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SYRS.

Financial health

How did Syros Pharmaceuticals financials performed over time
The total assets is 6% less than the total liabilities
The total assets has contracted by 41% YoY and by 21% from the previous quarter
Syros Pharmaceuticals's quick ratio has decreased by 37% YoY but it has increased by 12% QoQ
The equity has shrunk by 142% QoQ and by 109% YoY
Syros Pharmaceuticals's debt has decreased by 3.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.